Market Overview

UPDATE: Jefferies Raises PT on Bristol-Myers Squibb on Positive Outlook

Share:
Related BMY
Credit Suisse: We Prefer Pfizer, Bristol Over Pharma Peers
Bristol-Myers Squibb's Next 8 Months: What To Expect
Bristol-Myers Squibb (Investor's Business Daily)

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Bristol-Myers Squibb Co. (NYSE: BMY), and raised the price target from $41.00 to $45.00.

In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”

Bristol-Myers Squibb Co. closed on Tuesday at $40.83.

Latest Ratings for BMY

DateFirmActionFromTo
Apr 2015Deutsche BankMaintainsHold
Apr 2015Morgan StanleyUpgradesEqual-weightOverweight
Mar 2015Leerink SwannMaintainsOutperform

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (BMY)

Around the Web, We're Loving...